Corneal Transplantation and Innovative Therapies (TTIC)

Severe corneal disorders are among the leading causes of blindness worldwide.
The objective of the Clinical Research Group (GRC) 32 is to develop innovative approaches for treating blinding corneal disorders through prospective clinical trials and long-term longitudinal follow-up of large cohorts of patients. These innovative treatments include transplantation, cell therapy, regenerative therapies for corneal innervation and innovative treatments for keratoconus.
The GRC 32 brings together ophthalmologists and orthoptists ensuring the diagnosis and therapeutic management of patients and biologists and physicists ensuring the preclinical development of therapeutics and innovative imaging technologies.